471 related articles for article (PubMed ID: 16827709)
21. Onchocerca volvulus-specific antibody and cytokine responses in onchocerciasis patients after 16 years of repeated ivermectin therapy.
Mai CS; Hamm DM; Banla M; Agossou A; Schulz-Key H; Heuschkel C; Soboslay PT
Clin Exp Immunol; 2007 Mar; 147(3):504-12. PubMed ID: 17302900
[TBL] [Abstract][Full Text] [Related]
22. A community-based cross-sectional study of the epidemiology of onchocerciasis in unmapped villages for community directed treatment with ivermectin in Jimma Zone, southwestern Ethiopia.
Dana D; Debalke S; Mekonnen Z; Kassahun W; Suleman S; Getahun K; Yewhalaw D
BMC Public Health; 2015 Jul; 15():595. PubMed ID: 26130117
[TBL] [Abstract][Full Text] [Related]
23. Epidemiological studies of onchocerciasis in southern Benin.
Gallin M; Adams A; Kruppa TF; Gbaguidi EA; Massougbodji A; Sadeler BC; Brattig N; Erttmann KD
Trop Med Parasitol; 1993 Jun; 44(2):69-74. PubMed ID: 8367668
[TBL] [Abstract][Full Text] [Related]
24. Chemokines in onchocerciasis patients after a single dose of ivermectin.
Fendt J; Hamm DM; Banla M; Schulz-Key H; Wolf H; Helling-Giese G; Heuschkel C; Soboslay PT
Clin Exp Immunol; 2005 Nov; 142(2):318-26. PubMed ID: 16232219
[TBL] [Abstract][Full Text] [Related]
25. The impact of ivermectin on onchocerciasis in villages co-endemic for lymphatic filariasis in an area of onchocerciasis recrudescence in Burkina Faso.
Nikièma AS; Koala L; Sondo AK; Post RJ; Paré AB; Kafando CM; Kambiré RS; Sow B; Bougouma C; Dabiré RK; Traoré S
PLoS Negl Trop Dis; 2021 Mar; 15(3):e0009117. PubMed ID: 33647010
[TBL] [Abstract][Full Text] [Related]
26. Epidemiological evaluation of onchocerciasis along Ogun River System, southwest Nigeria.
Sam-Wobo SO; Adeleke MA; Jayeola OA; Adeyi AO; Oluwole AS; Ikenga M; Lawniye F; Gazama J; Kagni A; Kosoko TO; Agbeyangi O; Bankole S; Toé L; Mafiana CF; Yameogo L
J Vector Borne Dis; 2012 Jun; 49(2):101-4. PubMed ID: 22898482
[TBL] [Abstract][Full Text] [Related]
27. Onchocerciasis-associated epilepsy in the Democratic Republic of Congo: Clinical description and relationship with microfilarial density.
Siewe Fodjo JN; Mandro M; Mukendi D; Tepage F; Menon S; Nakato S; Nyisi F; Abhafule G; Wonya'rossi D; Anyolito A; Lokonda R; Hotterbeekx A; Colebunders R
PLoS Negl Trop Dis; 2019 Jul; 13(7):e0007300. PubMed ID: 31314757
[TBL] [Abstract][Full Text] [Related]
28. Parasitological and clinical characterization of Simulium neavei-transmitted onchocerciasis in western Uganda.
Fischer P; Kipp W; Bamuhiga J; Binta-Kahwa J; Kiefer A; Büttner DW
Trop Med Parasitol; 1993 Dec; 44(4):311-21. PubMed ID: 8134773
[TBL] [Abstract][Full Text] [Related]
29. Emergence of Onchocerca volvulus microfilariae from skin snips before and after treatment of patients with ivermectin.
Mössinger J; Schulz-Key H; Dietz K
Trop Med Parasitol; 1988 Dec; 39(4):313-6. PubMed ID: 3067322
[TBL] [Abstract][Full Text] [Related]
30. Comparison of serological and parasitological assessments of Onchocerca volvulus transmission after 7 years of mass ivermectin treatment in Mexico.
Rodríguez-Pérez MA; Danis-Lozano R; Rodríguez MH; Bradley JE
Trop Med Int Health; 1999 Feb; 4(2):98-104. PubMed ID: 10206263
[TBL] [Abstract][Full Text] [Related]
31. Impact of four years of large-scale ivermectin treatment with low therapeutic coverage on the transmission of Onchocerca volvulus in the Mbam valley focus, central Cameroon.
Pion SD; Clément MC; Boussinesq M
Trans R Soc Trop Med Hyg; 2004 Sep; 98(9):520-8. PubMed ID: 15251400
[TBL] [Abstract][Full Text] [Related]
32. Onchocerca volvulus infection and serological prevalence, ocular onchocerciasis and parasite transmission in northern and central Togo after decades of Simulium damnosum s.l. vector control and mass drug administration of ivermectin.
Komlan K; Vossberg PS; Gantin RG; Solim T; Korbmacher F; Banla M; Padjoudoum K; Karabou P; Köhler C; Soboslay PT
PLoS Negl Trop Dis; 2018 Mar; 12(3):e0006312. PubMed ID: 29494606
[TBL] [Abstract][Full Text] [Related]
33. Effect of ivermectin treatment on microfilarial load in patients with Onchocerca volvulus in Bebeka, Ethiopia.
Kebede A; Taticheff S; Bulto T; Workneh W; Tilahun D
Ethiop Med J; 1993 Apr; 31(2):127-35. PubMed ID: 8513779
[TBL] [Abstract][Full Text] [Related]
34. Differential susceptibility of Onchocerca volvulus microfilaria to ivermectin in two areas of contrasting history of mass drug administration in Cameroon: relevance of microscopy and molecular techniques for the monitoring of skin microfilarial repopulation within six months of direct observed treatment.
Abong RA; Amambo GN; Chounna Ndongmo PW; Njouendou AJ; Ritter M; Beng AA; Esum ME; Deribe K; Fru-Cho J; Fombad FF; Nji TM; Enyong PI; Poole CB; Pfarr K; Hoerauf A; Carlow CKS; Wanji S
BMC Infect Dis; 2020 Oct; 20(1):726. PubMed ID: 33008333
[TBL] [Abstract][Full Text] [Related]
35. Onchocerciasis in the Amazonian focus of southern Venezuela: altitude and blackfly species composition as predictors of endemicity to select communities for ivermectin control programmes.
Vivas-Martinez S; Basáñez MG; Grillet ME; Weiss H; Botto C; García M; Villamizar NJ; Chavasse DC
Trans R Soc Trop Med Hyg; 1998; 92(6):613-20. PubMed ID: 10326102
[TBL] [Abstract][Full Text] [Related]
36. Onchocerciasis in Imo state, Nigeria (2): the prevalence, intensity and distribution in the upper Imo river basin.
Dozie I; Onwuliri C; Nwoke B
Int J Environ Health Res; 2004 Oct; 14(5):359-69. PubMed ID: 15385215
[TBL] [Abstract][Full Text] [Related]
37. Dynamics of Onchocerca volvulus microfilarial densities after ivermectin treatment in an ivermectin-naïve and a multiply treated population from Cameroon.
Pion SD; Nana-Djeunga HC; Kamgno J; Tendongfor N; Wanji S; Njiokou F; Prichard RK; Boussinesq M
PLoS Negl Trop Dis; 2013; 7(2):e2084. PubMed ID: 23469307
[TBL] [Abstract][Full Text] [Related]
38. Ivermectin: reduction in prevalence and infection intensity of Onchocerca volvulus following biannual treatments in five Guatemalan communities.
Collins RC; Gonzales-Peralta C; Castro J; Zea-Flores G; Cupp MS; Richards FO; Cupp EW
Am J Trop Med Hyg; 1992 Aug; 47(2):156-69. PubMed ID: 1503185
[TBL] [Abstract][Full Text] [Related]
39. Community-based treatment of onchocerciasis with ivermectin: acceptability and early adverse reactions.
Pacque MC; Dukuly Z; Greene BM; Munoz B; Keyvan-Larijani E; Williams PN; Taylor HR
Bull World Health Organ; 1989; 67(6):721-30. PubMed ID: 2633887
[TBL] [Abstract][Full Text] [Related]
40. Single dose moxidectin versus ivermectin for Onchocerca volvulus infection in Ghana, Liberia, and the Democratic Republic of the Congo: a randomised, controlled, double-blind phase 3 trial.
Opoku NO; Bakajika DK; Kanza EM; Howard H; Mambandu GL; Nyathirombo A; Nigo MM; Kasonia K; Masembe SL; Mumbere M; Kataliko K; Larbelee JP; Kpawor M; Bolay KM; Bolay F; Asare S; Attah SK; Olipoh G; Vaillant M; Halleux CM; Kuesel AC
Lancet; 2018 Oct; 392(10154):1207-1216. PubMed ID: 29361335
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
